Compare SRRK & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRRK | TFX |
|---|---|---|
| Founded | 2012 | 1943 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.8B |
| IPO Year | 2018 | 1994 |
| Metric | SRRK | TFX |
|---|---|---|
| Price | $49.35 | $122.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 8 |
| Target Price | $56.17 | ★ $138.75 |
| AVG Volume (30 Days) | ★ 1.1M | 556.0K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.02% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,992,713,000.00 |
| Revenue This Year | N/A | $15.97 |
| Revenue Next Year | $534.24 | $5.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $27.07 | $100.18 |
| 52 Week High | $52.19 | $139.67 |
| Indicator | SRRK | TFX |
|---|---|---|
| Relative Strength Index (RSI) | 59.72 | 39.66 |
| Support Level | $45.46 | $117.57 |
| Resistance Level | $51.55 | $125.48 |
| Average True Range (ATR) | 2.07 | 3.87 |
| MACD | 0.38 | -0.98 |
| Stochastic Oscillator | 92.50 | 9.22 |
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Teleflex Inc is a provider of medical technology products focused on enhancing clinical benefits, improving patient and provider safety and reducing total procedural costs. It designs, develops, manufactures and supply medical devices used by hospitals and healthcare providers supporting high-acuity emergent procedures. The company has three reportable segments: Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). It derives maximum revenue from Americas. Its products includes: Anaesthesia, Emergency Medicine, Interventional Cardiology/Radiology, Interventional Urology - UroLift System, Surgery, Urology, and Vascular Access.